SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo.

Amison, RT; Faure, M-E; O'Shaughnessy, BG; Bruce, KD; Hu, Y; Coates, A; Page, CP (2020) The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo. Pulm Pharmacol Ther, 61. p. 101884. ISSN 1522-9629 https://doi.org/10.1016/j.pupt.2019.101884
SGUL Authors: Coates, Anthony Robert Milnes Hu, Yanmin

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

HT61 is a small quinolone-derived compound previously demonstrated to exhibit bactericidal activity against gram-positive bacteria including methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). When combined with the classical antibiotics and antiseptics neomycin, gentamicin, mupirocin and chlorhexidine, HT61 demonstrated synergistic bactericidal activity against both MSSA and MRSA infections in vitro. In this study, we investigated the individual antimicrobial activity of HT61 alongside its capability to increase the efficacy of tobramycin against both a tobramycin sensitive laboratory reference strain (PAO1) and tobramycin resistant clinical isolates (RP73, NN2) of the gram-negative bacteria Pseudomonas aeruginosa (P. aeruginosa). Using broth microdilution methods, the MICs of HT61 against all strains were assessed, as well as the effect of HT61 in combination with tobramycin using both the chequerboard method and bacterial time-kill assays. A murine model of pulmonary infection was also used to evaluate the combination therapy of tobramycin and HT61 in vivo. In these studies, we demonstrated significant synergism between HT61 and Tobramycin against the tobramycin resistant P. aeruginosa strains RP73 and NN2, whilst an additive/intermediate effect was observed for P. aeruginosa strain PA01 which was further confirmed using bacterial time kill analysis. In addition, the enhancement of tobramycin by HT61 was also evident in in vitro assays of biofilm eradication. Finally, in vivo studies revealed analogous effects to those observed in vitro with HT61 when administered in combination with tobramycin against each of the three P. aeruginosa strains at the highest tested dose (10 mg/kg).

Item Type: Article
Additional Information: © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
Keywords: 1103 Clinical Sciences, 1115 Pharmacology and Pharmaceutical Sciences, Respiratory System
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Pulm Pharmacol Ther
ISSN: 1522-9629
Language: eng
Dates:
DateEvent
April 2020Published
27 December 2019Published Online
25 December 2019Accepted
Publisher License: Creative Commons: Attribution 4.0
PubMed ID: 31887372
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/111531
Publisher's version: https://doi.org/10.1016/j.pupt.2019.101884

Actions (login required)

Edit Item Edit Item